Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989325 · ClinicalTrials.gov registry record · Phase 2
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT01989325 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 77 participants.
The verdict
NCT01989325, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.
Interventions
- DRUG Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
- DRUG Carfilzomib, proteasome inhibitor; intravenous
- DRUG Filanesib, KSP(Eg5) inhibitor; intravenous
- DRUG Dexamethasone, steroid; oral or intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989325
The ClinicalTrials.gov registry entry for NCT01989325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous is the first listed.
NCT01989325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989325 about?
NCT01989325 is a clinical study titled "A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma". This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzo...
What is the current status of trial NCT01989325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2013-11. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01989325?
The interventions under investigation include: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous (DRUG), Carfilzomib, proteasome inhibitor; intravenous (DRUG), Filanesib, KSP(Eg5) inhibitor; intravenous (DRUG), Dexamethasone, steroid; oral or intravenous (DRUG).
Who is sponsoring clinical trial NCT01989325?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.